Fourth-quarter earnings at JPMorgan Chase, Wells Fargo, Goldman Sachs, and Citigroup beat analysts’ estimates.

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

As spot Bitcoin exchange-traded funds (ETFs) mark their first anniversary and Ethereum ETFs reach the six-month milestone, ...

US stocks surged on Wednesday, fueled by a slowdown in core inflation and better-than-expected earnings from major banks. The ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

SoundHound AI (SOUN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

Wall Street stocks rose after in the bell in New York after US inflation climbed last month according to official figures.

Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...